AI biotech firm pushes limits of human lifespan
Breakthroughs in AI drug discovery are driving new efforts to combat ageing, with Insilico Medicine leading projects that combine machine learning, automation and biotechnology.
Longevity research is gaining momentum as AI transforms the way scientists search for new medicines. Insilico Medicine, founded by Alex Zhavoronkov in 2014, combines machine learning and automation to study ageing and accelerate drug discovery.
Company research focuses on identifying biological targets linked to ageing and developing molecules to treat related diseases. Several experimental treatments have already received Investigational New Drug clearance, allowing them to move towards human clinical trials.
Insilico also became the first AI-driven biotech company to list on the Hong Kong Stock Exchange, raising HK$2.28 billion in its public offering. Zhavoronkov said careful financial planning was essential because enthusiasm around AI could still form a market bubble.
Expansion plans now include deeper partnerships across China and the Middle East. A new collaboration in the UAE aims to build regional AI drug discovery programmes and diversify economies beyond oil.
Beyond medicines, Zhavoronkov envisions integrated biotech ecosystems where living spaces, healthcare and research operate together. Such hubs allow scientists and citizens to contribute health data that helps develop future treatments.
Would you like to learn more about AI, tech and digital diplomacy? If so, ask our Diplo chatbot!